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Background: The aim of this study was to compare mineral metabolism between
anuric and nonanuric chronic hemodialysis patients, and determine the differences
in phosphate control between the two groups.
Methods: A total of 77 chronic hemodialysis patients were enrolled in this cross-
sectional study from January 2012 to February 2012. Patient demographics,
laboratory ﬁndings, medication histories, and vascular calciﬁcation scores were
collected. We divided the patients into anuric and nonanuric groups according to
the residual renal function and then compared their clinical features. Multivariate
binary regression analysis was used in each group to determine the independent
factors related to phosphate control.
Results: The mean patient age was 59.27713.95 years, and 57.1% of patients were
anuric. In anuric patients, dialysis vintage was signiﬁcantly longer, but the mean Kt/V
was not different between groups. Serum phosphate, ﬁbroblast growth factor (FGF)-23,
and Ca/P products were signiﬁcantly higher, and 1,25(OH)2D3 levels were signiﬁcantly
lower in the anuric patients, although the intact parathyroid hormone and 25(OH)D
levels were not different. In anuric patients, LnFGF-23 [hazard ratio (HR) 2.894, 95%
conﬁdence interval (CI) 1.294–6.474, P¼0.010] was an independent factor predictive
of phosphate control. However, in the nonanuric patients, glomerular ﬁltration rate
(HR 0.409, 95% CI 0.169–0.989, P¼0.047) and blood urea nitrogen (HR 1.090, 95% CI
1.014–1.172, P¼0.019) were independent factors predictive of phosphate control.
Conclusion: In chronic hemodialysis patients, preservation of residual renal function is
a signiﬁcant determinant of phosphate control, and the factors associated with
phosphate control is different depending on the residual renal function status.
In the anuric patients, FGF-23 is most signiﬁcantly associated with phosphate control;
however, glomerular ﬁltration rate and blood urea nitrogen are more important than
FGF-23 in the nonanuric HD patients.
& 2014. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).n Society of Nephrology. Published by Elsevier. This is an open access article under the CC BY-NC-ND
c-nd/4.0/).
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Residual renal function (RRF) is an important determinant
of mortality and morbidity in chronic dialysis patients. In
previous studies, the degree of RRF was found to be inversely
associated with the severity of left ventricular hypertrophy
and cardiovascular death in peritoneal dialysis patients [1,2].
Preserved RRF was also observed to be associated with better
all-cause and cardiac-speciﬁc mortality in hemodialysis (HD)
patients [3,4]. These associations may be related to the better
clearance of mid to large molecular uremic toxin and ﬂuid
removal from the residual kidney in nonanuric dialysis
patients [5,6].
Phosphate, which is excreted through urine, is the key
molecule in chronic kidney disease-mineral and bone disorder
(CKD-MBD). Under normal physiologic conditions, phosphate
removal is determined mainly by the expression of type II
Na–Pi cotransporters at the tubular epithelium [7], which are
controlled by dietary phosphate, parathyroid hormone (PTH),
vitamin D, and ﬁbroblast growth factor-23 (FGF-23) [8,9].
In chronic dialysis patients with RRF, phosphate can be
excreted through the remnant nephron; however, in anuric
dialysis patients, serum phosphate cannot be excreted through
urine. Therefore, phosphate control may differ depending on
the RRF status.
In this study, we aimed to compare mineral metabolism
between anuric and nonanuric chronic HD patients and
determine the differences in phosphate control between these
groups according to RRF.Table 1. Causes of end-stage renal disease
Diagnosis %
Diabetes 53.25
Glomerulonephritis 20.78
Hypertension 14.28
ADPKD 6.49
Neurogenic bladder 3.89
Unknown 1.29
Data are presented as %.
ADPKD, autosomal dominant polycystic kidney disease.Methods
Participants
From January 2012 to February 2012, a total of 77 HD
patients from our dialysis unit were enrolled in this study.
All patients were older than 18 years and undergoing main-
tenance HD therapy for end-stage renal disease for more than
3 months. The participants were dialyzed thrice weekly for
more than 4 hours per session, using low-ﬂux membranes. The
standard dialysate calcium concentration was 3.5 mEq/L.
Exclusion criteria included severe malnutrition, acute infec-
tion, hepatic dysfunction, and malignancy. Approval of the
local ethics committee was obtained for this study, and all
patients provided written informed consent.
Data collection
Demographics and medical histories were reviewed; dialy-
sis treatment parameters such as dialysis vintage, blood ﬂow
rate, and single-pool Kt/V were assessed; and nutritional
markers, such as normalized protein nitrogen appearance
(nPNA), subjective global assessment (SGA), total protein,
albumin, and total cholesterol levels were checked. Biochem-
ical CKD-MBD factors and associated medication histories
during the study period were collected. All the predialysis
blood samples were obtained for routine laboratory assess-
ment by standard techniques, and a part of these samples was
stored at 801C for performing the enzyme-linked immuno-
sorbent assay (ELISA) study in all patients. Analysis of serum
calciumwas performed by the ortho-cresolphthalein complex-
one method using a Roche/Hitachi Modular-DP analyzer(Roche Diagnostics, Basel, Switzerland); calcium levels were
corrected for serum albumin. Analysis of serum phosphate was
performed by the phosphomolybdate reduction method using
a Roche/Hitachi Modular-DP analyzer (Roche Diagnostics). The
serum level of intact PTH (iPTH) was assessed by a total iPTH
immunoradiometric assay, which quantiﬁes both PTH(1–84)
and the N-truncated PTH fragments. Serum 25(OH)D and 1,25
(OH)2D3 levels were measured using a radio immunoassay.
Serum FGF-23 and serum fetuin A levels were measured using
an ELISA kit (ELISA, Immutopics, San Clemente, CA, USA—for
FGF-23; ELISA, R&D Systems, Minneapolis, MN, USA—for feutin A),
according to the manufacturer’s protocol.
Calculations and deﬁnitions
We deﬁned anuria as a 24-hour urine output of o100 mL,
and the glomerular ﬁltration rate (eGFR) of the anuric patients
was estimated to be 0.00 mL/minute/1.73 m2. For the non-
anuric patients, GFR was estimated by the numerical averages
of the 24-hour creatinine clearance and urea nitrogen clear-
ance. A 24-hour urine collection was made after the longest
interdialysis period. A cardiovascular event was deﬁned as
myocardial infarction, stroke, or transient ischemic attack.
Single-pool Kt/V (spKt/V) was calculated using the natural
logarithm formula [10], and the nPNA was calculated accord-
ing to the method of Bergström et al [11]. The optimal
phosphate level was deﬁned as the phosphate level between
2.5 mg/dL and 4.5 mg/dL, which is considered a normal value
in our clinic. All medications were prescribed according to the
2009 Kidney Disease: Improving Global Outcome CKD-MBD
treatment guidelines.
Aortic arch calciﬁcations were calculated based on posterior–
anterior plain chest X-rays, using Ogawa et al’s method [12], by a
physician who was independent of this study. The intraobserver
variability of this method was 5.3%.
Statistical analysis
Data were analyzed using SPSS for Windows, version 17.0
(SPSS Inc., Chicago, IL, USA). For continuous variables, the
mean 7 standard deviation was used for normally distributed
data; otherwise, the median was shown. Differences between
the two groups were assessed using a Student t test or Chi-
square test, as appropriate. Pearson or Spearman correlation
coefﬁcients were used to test the correlation between eGFR
and other variables. To evaluate the inﬂuence of parameters on
the control of optimal phosphate levels, nonparametric vari-
ables were Ln-transformed to achieve normality; after trans-
formation of the variables, we performed binary logistic
regression analysis. A P value of o0.05 was considered
statistically signiﬁcant.
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Patent characteristics according to RRF
A total of 77 patients were enrolled in this study. The mean
patient age was 59.27713.95 years, and 59.7% of patients
were male. Diabetes was the most common cause of end-stage
renal disease, the various causes of which are listed in Table 1.
In our study, 57.1% (N¼44) of the patients were anuric.
Dialysis vintage was signiﬁcantly longer in the anuric patients
than in the nonanuric patients. The spKt/V was not signiﬁ-
cantly different, and a minimally adequate dialysis dose
(spKt/V41.2) was equally achieved in both groups. Nutritional
factors, including nPNA and SGA, were not signiﬁcantly differ-
ent. Regarding the biochemical CKD-MBD factors, serum
phosphate, Ca/P product, and FGF-23 levels were signiﬁcantly
lower and 1,25(OH)2D3 levels were signiﬁcantly higher in the
nonanuric patients, although the frequency of prescribed
medications for phosphate control was not signiﬁcantly dif-
ferent between groups. However, serum iPTH and 25(OH)D
levels were not different, according to the RRF status. For the
factors related to vascular calciﬁcation, serum fetuin A levels
were similar, and the frequency of aortic arch calciﬁcation orTable 2. Baseline characteristics according to the urine output status
Variables Nonanuric patients
N 33
Age (y) 56.75714.24
Male 48
DM 18.2
HT 75.8
Hx of CVE 37.0
GFR (mL/min/1.73 m2) 6.4072.65
Dialysis factor
Dialysis vintage (mo) 20.73716.87
BFR (mL/min) 260.00715.61
Kt/V 1.5570.37
Nutrition factors
nPNA (g/kg/d) 1.0270.26
SGA 6.7070.59
Total protein (g/dL) 6.7570.52
Albumin (g/dL) 3.9670.48
Total cholesterol (mg/dL) 147.91729.73
BUN (mg/dL) 54.67719.22
Creatinine (mg/dL) 7.9272.78
Hb (g/dL) 10.2971.03
Biochemical CKD-MBD factors
Corrected calcium (mg/dL) 9.0970.73
Phosphate (mg/dL) 4.3271.0
CaP (mg2/dL2) 38.9679.75
ALP (IU/L) 73.15730.37
FGF-23 (pg/mL) 856.2572,297.58
iPTH (pg/mL) 135.517105.62
25(OH)D (ng/mL) 11.4575.80
1,25(OH)2D3 (pg/mL) 13.0377.70
Optimal phosphate group 59.4
Medications for the phosphate control
Calcium acetate 24.7
Sevelamer 2.6
Lanthanum 0
Vitamin D 5.2
Vascular calciﬁcation
Presence of AoAC 17.3
AoACS (%) 12.69719.85
Fetuin A (mg/mL) 412.12793.99
Data are presented as % or mean7SD, unless otherwise indicated.
ALP, alkaline phosphatase; AoAC, aortic arch calciﬁcation; AoACS, aortic ar
CKD-MBD, chronic kidney disease-mineral and bone disorder; DM, diabetes
rate; Hb, hemoglobin; HT, hypertension; Hx of CVE, history of cardiovascul
nitrogen appearance; SD, standard deviation; SGA, subjective global assessmthe aortic arch calciﬁcation score was not signiﬁcantly differ-
ent between groups (Table 2).
With the unadjusted analysis, serum phosphate (r¼0.16,
P o 0.001) and FGF-23 (r¼0.18, P¼0.001) levels showed a
negative correlation with eGFR, whereas 1,25(OH)2D3 (r¼0.79,
P o 0.001) showed a positive correlation. However, iPTH,
alkaline phosphatase, and 25(OH)D levels did not show any
correlation with eGFR.Factors associated with phosphate control in all patients
We further divided the patients into two groups according to
the achievement of optimal phosphate control. Of the patients,
44.1% (N¼34) achieved optimal phosphate control, and in
none of them the phosphate level was lower than 2.5 mg/dL.
The mean serum phosphate level was 3.5770.60 mg/dL in the
optimal phosphate control group and 5.9471.12 mg/dL in the
poor phosphate control group. In the optimal phosphate control
group, serum FGF-23 (335.867390.33 pg/mL vs. 3,313.837
5.36 pg/mL, P¼0.003), blood urea nitrogen (BUN; 50.397
14.60 mg/dL vs. 67.95717.47 mg/dL, Po0.001), creatinine (7.367
2.37 mg/dL vs. 10.0172.51 mg/dL, Po0.001) and CaP levelsAnuric patients P
44
62.64713.00 0.986
61 0.737
33.8 0.147
61.4 0.182
38.1 0.845
0.0070.00 <0.001
41.73725.94 0.031
265.45721.93 0.228
1.4870.21 0.274
1.1070.27 0.865
6.7070.83 0.728
6.9770.56 0.473
4.1470.43 0.398
150.09732.63 0.385
64.34716.79 0.867
9.5372.59 0.479
10.7271.32 0.449
9.1870.76 0.860
5.3271.66 0.017
49.53716.06 0.025
92.48752.05 0.068
2,849.0975,141.40 0.002
156.937140.24 0.238
11.0573.96 0.739
9.6773.46 0.020
31.8 0.014
32.5 0.737
9.1 0.183
1.3 0.383
6.5 0.918
25.3 0.758
13.95725.14 0.589
429.097130.59 0.770
ch calciﬁcation score; BFR, blood ﬂow rate; BUN, blood urea nitrogen;
mellitus; FGF-23, ﬁbroblast growth factor-23; GFR, glomerular ﬁltration
ar event; iPTH, intact parathyroid hormone; nPNA, normalized protein
ent.
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signiﬁcantly lower and eGFR (4.3274.26 mL/minute/1.73 m2 vs.
1.4972.42 mL/minute/1.73 m2, Po0.001) and 1,25(OH)2D3
level (13.7677.55 pg/mL vs. 9.3273.64 pg/mL, P¼0.003) were
statistically higher than in the poor phosphate control group.Table 3. Multivariate analysis that relates to predialysis serum phospha
Variables Univariate model
HR 95% CI
LnFGF-23 (pg/mL) 2.371 1.495–3.761
1,25(OH)2D3 (pg/mL) 0.824 0.709–0.957
GFR (mL/min/1.73 m2) 0.779 0.668–0.909
BUN (mg/dL) 1.075 1.034–1.117
Cr (mg/dL) 1.542 1.211–1.963
Age (y) 0.951 0.914–0.989
n Adjusted age, sex, LnFGF-23, 1,25(OH)2D3, GFR, BUN, and Cr.
BUN, blood urea nitrogen; CI, conﬁdence interval; Cr, creatinine; GFR, gl
ﬁbroblast growth factor-23.
Table 4. Comparisons of phosphate control according to the residual re
Variables Nonanuric patients
Optimal P control Poor P control
Number 20 13
Age (y) 66.37710.54 58.23715.03
Male 57.9 53.8
DM 47.4 38.5
HT 73.7 76.9
Hx of CVE 41.7 36.7
GFR (mL/min/1.73 m2) 7.2872.89 5.2071.84
Dialysis factor
Dialysis vintage (mo) 22.58718.26 16.31713.80
BFR (mL/min) 257.3779.91 260.76718.91
Kt/V 1.5870.42 1.5270.30
Nutrition factors
nPNA (g/kg/d) 1.0270.31 1.0270.19
SGA score 6.7470.56 6.6470.67
Total protein (g/dL) 6.6470.41 6.9070.63
Albumin (g/dL) 3.9970.39 3.9270.60
Total cholesterol (mg/dL) 145.32730.49 151.69729.36
BUN (mg/dL) 46.68714.89 67.27719.16
Creatinine (mg/dL) 6.7372.35 9.4772.63
Hb (g/dL) 10.3771.14 10.1670.92
Biochemical CKD-MBD factors
Corrected calcium (mg/dL) 9.4870.66 9.5170.73
Phosphate (mg/dL) 3.5970.58 5.3570.60
CaP (mg2/dL2) 32.5275.46 48.3776.24
ALP (IU/L) 79.05727.58 67.77732.93
FGF-23 (pg/mL) 314.237456.39 658.317375.96
LnFGF-23 (pg/mL) 4.9271.33 6.2170.92
iPTH (pg/mL) 163.757115.07 101.92781.05
1,25(OH)2D3 (ng/mL) 15.2778.71 10.4875.08
Medications for the phosphate control
Calcium acetate 63.2 53.8
Average dose (mg/d) 597.897542.95 1301.6771625.64
Sevelamer 070 15.4
Average dose (mg/d) 0 369.237901.28
Lanthanum 0 0
Average dose (mg/d) 070 070
Calcitriol 21.1 0
Average dose (mcg/d) 0.0570.13 070
Vascular calciﬁcation
Presence of AoAC 47.4 30.8
AoACS score 15.78722.76 8.17714.29
Fetuin A (mg/mL) 381.68793.15 459.89781.49
Data are presented as % or mean 7 SD.
ALP, alkaline phosphatase; AoAC, aortic arch calciﬁcation; AoACS, aortic ar
CKD-MBD, chronic kidney disease-mineral and bone disorder; DM, diabetes
rate; Hb, hemoglobin; HT, hypertension; Hx of CVE, history of cardiovascul
nitrogen appearance; SD, standard deviation; SGA, subjective global assessmUni- and multivariate regression analyses were performed after
adjusting for these factors.
In the univariate analysis, LnFGF-23, 1,25(OH)2D3, GFR, BUN,
creatinine, and age were signiﬁcant factors; however, in
the multivariate regression model, LnFGF-23, 1,25(OH)2D3,te level, in all patientsn
Multivariate model
P HR 95% CI P
<0.001 1.991 1.147–3.458 0.014
0.004 0.777 0.641–0.942 0.010
0.001 0.776 0.620–0.970 <0.001
<0.001
<0.001
0.012
omerular ﬁltration rate; HR, hazard ratio; LnFGF-23, log-transformed
nal function in chronic hemodialysis patients
Anuric patients
P Optimal P control Poor P control P
14 30
0.081 61.2577.51 54.74715.98 0.078
0.821 75.0 54.8 0.306
0.618 75.0 54.8 0.306
0.835 91.7 51.6 0.032
0.763 41.7 36.7 0.763
0.030 0 0 –
0.303 45.92724.24 41.35726.29 0.605
0.560 265.00723.16 266.13722.01 0.886
0.648 1.4670.21 1.5070.21 0.517
0.999 1.0370.19 1.1370.29 0.246
0.664 6.4271.16 6.8170.65 0.171
0.169 7.0670.64 6.9470.54 0.510
0.071 4.0170.32 4.1870.46 0.246
0.560 147.33723.18 151.16735.90 0.735
0.002 55.67714.84 68.10716.54 0.028
0.004 8.3972.14 10.0972.58 0.048
0.581 10.4771.52 10.8271.27 0.456
0.905 9.6370.72 9.4270.64 0.364
<0.001 3.4370.56 6.1371.24 <0.001
<0.001 31.7876.29 56.39713.11 <0.001
0.302 105.50754.65 87.10751.83 0.310
0.045 372.127304.20 3919.3275846.95 0.003
0.009 5.5071.12 7.0971.71 0.007
0.105 117.197101.73 167.617151.45 0.295
0.100 11.1974.21 8.7672.65 0.047
58.3 64.5
0.598 650.837769.37 1088.6771082.94 0.210
0 22.6
0.157 070 541.9471020.06, 0.006
0 3.2
070 48.397269.41 0.540
8.3 12.9
0.128 0.0270.07 0.0270.06 0.854
0.348 41.7 45.2 0.836
0.294 9.37713.19 15.72728.45 0.464
0.030 409.89795.03 439.277142.92 0.551
ch calciﬁcation score; BFR, blood ﬂow rate; BUN, blood urea nitrogen;
mellitus; FGF-23, ﬁbroblast growth factor-23; GFR, glomerular ﬁltration
ar event; iPTH, intact parathyroid hormone; nPNA, normalized protein
ent.
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phosphate control (Table 3).
Factors associated with phosphate control in nonanuric
patients
Among the 33 nonanuric patients, 59.4% (N¼20) achieved
optimal phosphate control, and the use of phosphate-binding
agents in this group was not signiﬁcantly different from that in
the poor phosphate control group (63.2% vs. 69.2%, P¼0.598).
Other nonanuric patient characteristics according to the phos-
phate control are presented in Table 4.
In the univariate analysis, LnFGF-23, BUN, creatinine level, and
GFR were statistically signiﬁcant; however, in the multivariate
analysis, GFR [hazard ratio (HR) 0.409, 95% conﬁdence interval
(CI) 0.169–0.989, P¼0.047] and BUN (HR 1.090, 95% CI 1.014–
1.172, P¼0.019) were independent factors predictive of phos-
phate control (Table 5).
Factors associated with phosphate control in anuric patients
Only 31.8% (N¼14) of the anuric patients achieved optimal
phosphate control, although the frequency of using phosphate-
binding agents was higher in the poor phosphate control group
(90.3% vs. 58.3%, P¼0.028). A detailed description of anuric HD
patient characteristics, according to the phosphate control, is
presented in Table 4.
In the univariate analysis model, LnFGF-23, 1,25(OH)2D3,
BUN, and creatinine levels were statistically signiﬁcant; how-
ever, in the multivariate regression analysis, only LnFGF-23
(HR 2.894, 95% CI 1.294–6.474, P¼0.010) was predictive of
phosphate control (Table 5).Discussion
Traditionally, the signiﬁcance of RRF has been emphasized
in peritoneal dialysis patients, but its importance has often
been overlooked in HD patients. The signiﬁcance of RRF in
CKD-MBD in HD patients was ﬁrst described by Viaene et al
[13]. In their study, RRF was found to be an important
determinant of FGF-23 and phosphate control in HD patients.
Furthermore, Penne et al [14] reported in their study that GFR
was negatively correlated with the phosphate binder dose inTable 5. Regression analysis of factors relate to predialysis serum phos
Variables Univariate model
HR 95% CI
Nonanuric patients
LnFGF-23 (pg/mL) 2.539 1.170–5.511
GFR (mL/min/1.73 m2) 0.633 0.403–0.996
BUN (mg/dL) 1.090 1.020–1.164
Creatinine (mg/dL) 1.542 1.101–2.160
Anuric patients
LnFGF-23 (pg/mL) 2.064 1.135–3.754
1,25(OH)2D3 (pg/mL) 0.793 0.621–1.013
BUN (mg/dL) 1.055 1.003–1.110
Creatinine (mg/dL) 1.408 0.984–2.014
n Adjusted age, sex, LnFGF-23, GFR, BUN, Cr, and fetuin A, in nonanuric pat
sevelamer in anuric patients.
BUN, blood urea nitrogen; CI, conﬁdence interval; GFR, glomerular ﬁltratio
factor-23.HD patients, and a GFR of 44.13 mL/minute/1.73 m2 was an
important predictor of adequate phosphate control.
Our study also demonstrated the signiﬁcance of RRF for
phosphate control in maintenance HD patients. Mineral meta-
bolism was closer to normal physiology in the nonanuric
patients than in the anuric patients; phosphate control was
better, FGF-23 levels were signiﬁcantly lower, and 1,25(OH)2D3
levels were signiﬁcantly higher in the nonanuric patients, and
all these factors showed meaningful correlation with eGFR.
This superiority of phosphate control in the nonanuric HD
patients may be attributed to the occurrence of phosphaturia
through the remnant nephron. In the nonanuric patients,
excretion of phosphate through urine could inhibit further
increase of serum FGF-23, and controlled FGF-23 secretion
allowed the conversion of 25(OH)D to 1,25(OH)2D3 [15].
The unique point of our study was that factors associated
with phosphate control were found to differ according to
the RRF status. For optimal phosphate control, FGF-23, as
expected, was a signiﬁcant factor in the anuric patients;
however, in the nonanuric patients, BUN and GFR were the
independent factors that were predictive of phosphate control,
instead of FGF-23. Recently, Wang et al [16] reported data
similar to that of our study. In their study of 134 maintenance
HD patients, iPTH, FGF-23, and nPNA were the independent
determinants of phosphate control in the anuric patients. For
the nonanuric patients, only GFR and female sex were the
independent determinants of phosphate control.
Traditionally, FGF-23 was regarded as a master regulator of
phosphate homeostasis [17,18]. However, as observed in our
and Wang et al’s [16] studies, FGF-23 was not a determinant of
phosphate control in the nonanuric HD patients. This might be
the differences in the amount of phosphate excretion through
the remnant nephron. In normal physiology, klotho, which is a
membrane-bound cofactor that is required for binding FGF-23
to its receptor in the renal tubule [19], plays an important role
in the FGF-23 action. However, in patients with maintenance
HD, klotho level is already decreased and the amount of
phosphaturia seems more likely to be dependent on GFR.
Thus, GFR appears to be a fundamental factor for mineral
metabolism in maintenance HD patients.
In this study, BUN was also a determinant of phosphate control
in the nonanuric patients. Although BUN has an association with
GFR as a ﬁltration marker, it is also an important nutritional
marker, especially for dietary phosphate. A higher BUN representsphate level, according to the residual renal functionn
Multivariate model
P HR 95% CI P
0.018
0.048 0.409 0.169–0.989 0.047
0.011 1.090 1.014–1.172 0.019
0.012
0.018 2.894 1.294–6.474 0.010
0.063
0.039
0.061
ients. Adjusted age, sex, HT, LnFGF-23, BUN, Cr, 1.25(OH)2D3 and use of
n rate; HR, hazard ratio; LnFGF-23, log-transformed ﬁbroblast growth
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fore, it is reasonable to assume that a higher BUN represents a
higher dietary phosphate intake, and dietary intake is an impor-
tant factor for phosphate control in nonanuric HD patients. nPNA
and SGA were also measured as nutritional factors; however, they
did not correlate with BUN in this study. The nPNAwas measured
using Bergström et al’s [11] equation, which did not account for
urinary protein loss, thus underestimating the nutrition status of
nonanuric patients. SGA had several objective components; thus,
slipshod attitude of the patients could incorrectly estimate nutri-
tional status. A previous study also pointed out these problems
[21]; thus, SGA could not reﬂect nutritional status correctly in
this study.
FGF-23 and PTH stimulate phosphaturia in a similar manner by
reducing phosphate reclamation through Na/Pi IIa, IIc cotranspor-
ters [8,9,18]. However, in our study, the role of iPTH in phosphate
metabolism appeared to be less signiﬁcant than that of FGF-23,
and iPTH appeared to be less affected by RRF status, which is also
consistent with the previous studies [13,14,16]. The reasons for
these might be the combined regulation of calcium homeostasis in
the CKD-MBD and complex interactions of FGF-23, iPTH, and 1,25
(OH)2D3 [22]. However, no clear relationships between FGF-23,
iPTH, and RRF are revealed, thus warranting further investigation.
In our cross-sectional study, vascular calciﬁcation was not
affected by RRF. Atherosclerosis is known to have a positive
correlation with FGF-23 [23]; as serum FGF-23 levels were
signiﬁcantly higher in the anuric patients, we expected higher
vascular calciﬁcation rates in those patients. Although CKD-MBD is
one of themain factors for vascular calciﬁcation in dialysis patients
[24,25], other factors, such as age, diabetes mellitus, hypertension,
dialysis vintage, male gender, and calciﬁcation inhibitory factors (e.
g., fetuin-A), are also closely associated with vascular calciﬁcation
[26–29]. We were unable to establish a relationship between
vascular calciﬁcation and RRF in our study. Further prospective
observation studies are needed to address this point.
Our study has several limitations. First, we could not explain
the cause and effect relationships between phosphate, RRF, FGF-
23,1,25(OH)2D3, and iPTH, because we did not measure the degree
of phosphaturia in the nonanuric HD patients and did not control
serum phosphate level in the anuric HD patients. Second, the
sample size was small. Third, we did not control dietary phosphate
during the study period. However, our results are consistent with
previous data, and it is valuable to understand that phosphate
metabolism is somewhat different according to RRF in HD
patients.
In conclusion, RRF was found to be an important, possibly
fundamental, factor for CKD-MBD in maintenance HD patients.
In the anuric HD patients, FGF-23 was observed to be an
important determinant of phosphate control; however, in
nonanuric HD patients, GFR was more important than FGF-
23 for phosphate control.Conﬂicts of interest
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